AUSTIN, Texas, Nov. 18, 2025 /PRNewswire/ — Dastify Solutions, a leading U.S. medical billing and revenue cycle management (RCM) company, has released its 2025 Healthcare Billing Trends Report, revealing that nearly 30% of medical claims are denied or rejected on first submission, costing providers billions annually.
Industry sources confirm:
MGMA — https://www.mgma.com
CMS — https://www.cms.gov
Dastify Solutions processes more than 2 million claims annually, maintains a 98.5% clean-claim rate, and delivers 30–40% faster reimbursement using AI-driven automation and predictive denial analytics.
Learn more:
https://www.dastifysolutions.com/medical-billing/
Leadership Insights
“Front-end errors are still the top cause of preventable denials,” said Ricky Bell, Head of Operations.
“AI lets us catch issues before a claim ever reaches the payer.”
Anum Naveed, Director at Dastify Solutions, added:
“CMS, HIPAA, and payer updates shift constantly. Automated compliance is no longer optional—it’s necessary.”
HIPAA overview: https://www.hhs.gov/hipaa
Key Insights From the 2025 Report
Why This Matters for Providers
As billing complexity increases, practices using manual workflows face:
Dastify Solutions consistently outperforms national benchmarks:
Future of Medical Billing
The 2025 report highlights major shifts:
About Dastify Solutions
Dastify Solutions is an AI-powered RCM and medical billing company serving healthcare providers across all 50 U.S. states, covering more than 50 specialties. The company helps practices reduce denials, boost collections, and eliminate administrative burdens.
Visit: https://www.dastifysolutions.com/
Media Contact:
info@dastifysolutions.com
(512) 640-4218
SOURCE Dastify Solutions
TAMPA, FL / ACCESS Newswire / December 26, 2025 / Key TakeawaysWhat it claims: Nerve…
Integrated smart technology builds on TempraMed's proven VIVI platform, providing robust Temperature control with medication…
NORTHAMPTON, MA / ACCESS Newswire / December 26, 2025 / Specialized nutrition experts are key…
"Despite clear congressional mandates and FDA authorization, the Drug Enforcement Administration failed to act within…
WASHINGTON, Dec. 26, 2025 /PRNewswire/ -- Over the past decade, China has evolved from a biotechnology…
SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a…